Association between treatment-related adverse events and clinical outcomes in NSCLC patients receiving neoadjuvant immunochemotherapy: a retrospective study
Myelosuppression is negatively associated with favorable pathological outcomes in NSCLC patients undergoing neoadjuvant immunochemotherapy and serves as a potential predictor of EFS, offering valuable insights for guiding treatment decisions.
Authors
- Haifeng Lin (ORCID: https://orcid.org/0000-0001-9636-5335)
- Xueyuan Cao (ORCID: https://orcid.org/0000-0002-1982-1672)
- Hezhe Lu (ORCID: https://orcid.org/0009-0003-2408-2821)
- Y. Li (ORCID: https://orcid.org/0009-0001-4276-4370)
- Maoduo Zhang (ORCID: https://orcid.org/0000-0003-4366-4993)
- Lei Guo (ORCID: https://orcid.org/0000-0002-5089-7886)
- Yi Han
- Zhexin Ding
Institutions
- Capital Medical University (CN)
- Chinese Academy of Sciences (CN)
- Institute for Stem Cell Biology and Regenerative Medicine (IN)
- Beijing Chest Hospital (CN)
- University of Chinese Academy of Sciences (CN)
- Institute of Zoology (CN)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/03007995.2025.2587377
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00